A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Latest Information Update: 19 Dec 2023
At a glance
- Drugs Pemrametostat (Primary)
- Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Glioblastoma; Head and neck cancer; Male breast cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Ureteral neoplasms
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms METEOR-1
- Sponsors GlaxoSmithKline; GSK
- 12 Dec 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results reporting safety and efficacy data from part 2 dose expansion phase of this trial presented at the 47th European Society for Medical Oncology Congress
- 23 Jun 2022 Planned End Date changed from 29 Apr 2025 to 31 Aug 2023.